1
|
Diamant E, Ingels A, Bajeot A, Champy C, Vordos D, Seisen T, Roumiguié M, De La Taille A, Rouprêt M, Batista Da Costa J. Résultats comparés de la survie après cystectomie pour les tumeurs de la vessie n’infiltrant pas le muscle de haut risque : expérience multicentrique. Prog Urol 2020. [DOI: 10.1016/j.purol.2020.07.233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
2
|
Duquesne I, Champy C, Klap J, Chahwan C, Vordos D, de la Taille A, Salomon L. [When to introduce hormone therapy after total prostatectomy with positive lymph nodes? Study of the factors influencing the time of introduction of hormone therapy]. Prog Urol 2019; 29:981-988. [PMID: 31735682 DOI: 10.1016/j.purol.2019.09.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2019] [Revised: 09/26/2019] [Accepted: 09/28/2019] [Indexed: 11/26/2022]
Abstract
INTRODUCTION Adjuvant hormone therapy is the standard treatment after total prostatectomy with positive lymph node. However, this treatment has side effects and at the time of the PSA era and extensive lymph node dissection, this principle is questioned. The aim of this study is to describe the oncological characteristics of patients that may explain the delay in introducing hormone therapy in patients with positive lymph node. METHODS Monocentric, retrospective study of 161 patients from November 1988 to February 2018 in a single French University Hospital, having undergone radical prostatectomy with positive lymph nodes on pathology. For each patient, preoperative data (age, clinical stage, biopsy results, d'Amico classification) and postoperative data (pathological results, number of lymph nodes removed, number of positive lympnodes, recurrence free survival, specific survival and overall survival) were collected. The date of introduction of hormone therapy was noted and survival without hormonal therapy was established according to the Kaplan Meier curve. The pre- and post-operative oncological factors that could influence hormone therapy introduction were investigated with Chi2 and Student tests (statistically significant when P<0.05). RESULTS The mean number of lymph nodes removed was 12 [1-40]. The mean number of positive lymph nodes was 2.5 [1-24], the mean percentage of positive lymph nodes was 25% (2.5-100). After a mean follow-up of 95 months (3-354), 88 patients (54.6%) had no hormonal treatment. The average time to hormonal treatment was 40 months [0-310]. At 3 years, survival without hormone therapy was 52% and 51% at 5 years. Only the percentage of positive lymphnodes appeared to be a significant predictor of the introduction of hormone therapy. (29.32% vs. 21.99%, P=0.047). Hormone-free survival was significantly higher in patients with lymph node involvement less than 25% (P<0.0001) or with less than 2 positive lymph nodes (P=0.0294). CONCLUSION Lymph node invasion is a factor of poor prognosis after total prostatectomy and leads to introduce hormone therapy. Our study identified the percentage and number of positive lymph nodes as factors that identify patients who may be delayed in introducing this hormone therapy. LEVEL OF PROOF 3.
Collapse
Affiliation(s)
- I Duquesne
- Service d'urologie, CHU Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France.
| | - C Champy
- Service d'urologie, CHU Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| | - J Klap
- Service d'urologie, CHU Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| | - C Chahwan
- Service d'urologie, CHU Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| | - D Vordos
- Service d'urologie, CHU Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| | - A de la Taille
- Service d'urologie, CHU Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| | - L Salomon
- Service d'urologie, CHU Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| |
Collapse
|
3
|
Merzeau N, Champy C, Such M, Klapp J, Chahwan C, Vordos D, Hoznek A, Matignon M, Grimbert P, de la Taille A, Salomon L. [Evaluation of single kidney graft outcome in patients initially programmed for a dual kidney graft transplantation]. Prog Urol 2019; 29:340-346. [PMID: 31151914 DOI: 10.1016/j.purol.2019.04.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2018] [Revised: 02/16/2019] [Accepted: 04/18/2019] [Indexed: 11/26/2022]
Abstract
INTRODUCTION Kidney transplantation is championed as the gold standard treatment for patients with end-stage kidney disease. According to the biomedical agency, there is an increasing number of patients waiting for kidney transplantation. Faced with organ shortage, the use of marginal grafts may well increase the number of available kidney grafts. Occasionally, during dual kidney graft transplantation, the poor quality of one of the two grafts, or other specific circumstances, may lead to transplantation of only one of the two grafts. We have compared patient outcome concerning single kidney transplantation from an initial dual kidney graft with respect to dual kidney graft transplantation. MATERIAL Among 67 patients enrolled for a dual kidney graft, 39 dual kidney grafts (group 1) were compared with 12 grafts performed with only one of the two kidneys of a dual kidney graft (group 2) as well as 15 grafts performed following a classic kidney graft protocol (group 3). RESULTS The survival of grafts was respectively for groups 1, 2 and 3 of 100%, 72,5% and 75,4% (P=0.17). The survival of patients was respectively for groups 1, 2 and 3 of 78.3%, 89.9% and 87.8% (P=0.47). CONCLUSION Our study suggests that transplantation of a single kidney, initially proposed as dual kidney graft candidate, has satisfying results in terms of graft survival and patient mortality at the expense of poorer renal function in comparison to dual kidney graft. Indeed, there was no significant difference in the survival of patients and grafts. This seems promising taking into consideration that the aim of transplantation in elderly recipients is primarily to avoid dialysis, rather than having optimal post-transplantation kidney function. LEVEL OF EVIDENCE 4.
Collapse
Affiliation(s)
- N Merzeau
- Service d'urologie, hôpital Robert-Debré, rue du Général-Koenig, 51092 Reims cedex, France.
| | - C Champy
- Service d'urologie, hôpital Henri-Mondor, 51, avenue du Ml de Lattre-de-Tassigny, 94010 Créteil cedex, France
| | - M Such
- Service d'urologie, hôpital Henri-Mondor, 51, avenue du Ml de Lattre-de-Tassigny, 94010 Créteil cedex, France
| | - J Klapp
- Service d'urologie, hôpital Henri-Mondor, 51, avenue du Ml de Lattre-de-Tassigny, 94010 Créteil cedex, France
| | - C Chahwan
- Service d'urologie, hôpital Henri-Mondor, 51, avenue du Ml de Lattre-de-Tassigny, 94010 Créteil cedex, France
| | - D Vordos
- Service d'urologie, hôpital Henri-Mondor, 51, avenue du Ml de Lattre-de-Tassigny, 94010 Créteil cedex, France
| | - A Hoznek
- Service d'urologie, hôpital Henri-Mondor, 51, avenue du Ml de Lattre-de-Tassigny, 94010 Créteil cedex, France
| | - M Matignon
- Service de néphrologie, hôpital Henri-Mondor, 51, avenue du Ml de Lattre-de-Tassigny, 94010 Créteil cedex, France
| | - P Grimbert
- Service de néphrologie, hôpital Henri-Mondor, 51, avenue du Ml de Lattre-de-Tassigny, 94010 Créteil cedex, France
| | - A de la Taille
- Service d'urologie, hôpital Henri-Mondor, 51, avenue du Ml de Lattre-de-Tassigny, 94010 Créteil cedex, France
| | - L Salomon
- Service d'urologie, hôpital Henri-Mondor, 51, avenue du Ml de Lattre-de-Tassigny, 94010 Créteil cedex, France
| |
Collapse
|
4
|
Lenfant L, Verhoest G, Campi R, Parra J, Graffeille V, Masson-Lecomte A, Vordos D, De La Taille A, Roumiguie M, Lesourd M, Taksin L, Vaessen C, Ploussard G, Granger B, Rouprêt M. Comparaison des résultats périopératoires entre la reconstruction urinaire intracorporelle et extracorporelle après cystectomie robot-assistée pour cancer de vessie : une étude multicentrique française. Prog Urol 2018. [DOI: 10.1016/j.purol.2018.07.119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
5
|
Coraggio G, Loganadane V G, Husheng S, ghith-Neji S, Grellier N, Herve M, To N, Colson-Durand L, Jouhaud A, Fayolle-Campana M, Vordos D, Belkacemi Y. Hemostatic Radiation Therapy for Bladder Cancer-Related Hematuria in Patients Unfit for Surgery: The Impact of Fractionation Schedule. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
6
|
Coraggio G, Loganadane G, Husheng S, Ghith S, Grellier N, Hervé ML, To N, Colson L, Jouhaud A, Fayolle M, Vordos D, Belkacémi Y. Radiothérapie hémostatique dans le cancer de la vessie chez les patients inopérables : quel impact du fractionnement ? Cancer Radiother 2018. [DOI: 10.1016/j.canrad.2018.07.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
7
|
Michel C, Vordos D, Dumont C, Basset V, Meyer F, Gaudez F, Meria P, Cortesse A, Mongiat-Artus P, de la Taille A, Culine S, Desgrandchamps F, Masson-Lecomte A. [Impact of neoadjuvant chemotherapy on the peri-operative morbidity of radical cystectomy for muscle invasive bladder cancer]. Prog Urol 2018; 28:495-501. [PMID: 29997033 DOI: 10.1016/j.purol.2018.06.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2018] [Revised: 04/30/2018] [Accepted: 06/07/2018] [Indexed: 11/18/2022]
Abstract
INTRODUCTION Platinum-based neoadjvant chemotherapy (NAC) before radical cystectomy (RC) is the gold standard in the treatment of muscle invasive bladder cancer (MIBC). We aimed to compare the peri-operative morbidity in patients treated by NAC then RC and patients having RC alone. METHODS Between 1st January 2008 and 31st December 2015, we retrospectively included consecutive patients undergoing RC for MIBC in 2centers. We collected clinical, pathological and peri-operative data (30day post operative complications according to the Clavien-Dindo score, delayed complications, pathological results). Patients treated by NAC (NAC-RC group) before RC were compared to patients performing RC alone. The NAC-RC group received 1 to 6cycle of high-dose MVAC, MVAC or gemcitabine-cisplatine chemotherapy. Logistic regression identified independant factors of peri-operative complications. RESULTS We included 199 patients: 48in the NAC-RC group and 151in the RC group. Complications rate was 73.9% in the NAC-RC group versus 73.8% in the RC group (P=1.0). In multivariate analyses, only the Charlson score was associated with an increased risk of peri-operative complications (P=0.05). PT0 tumour rate was significantly higher in the NAC-CR group (50% vs 7%, P<0.001). CONCLUSION NAC does not increase the peri-operative morbidity of the RC. Patients' pre operative comorbidities is the main risk factor for peri-operative complications.
Collapse
Affiliation(s)
- C Michel
- Service d'urologie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France.
| | - D Vordos
- Service d'urologie, hôpital Henri-Mondor, 31, rue du Parc, 94000 Créteil, France.
| | - C Dumont
- Service d'oncologie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France.
| | - V Basset
- Service d'urologie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France.
| | - F Meyer
- Service d'urologie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - F Gaudez
- Service d'urologie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France.
| | - P Meria
- Service d'urologie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France.
| | - A Cortesse
- Service d'urologie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France.
| | - P Mongiat-Artus
- Service d'urologie, hôpital Henri-Mondor, 31, rue du Parc, 94000 Créteil, France.
| | - A de la Taille
- Service d'urologie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France.
| | - S Culine
- Service d'oncologie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - F Desgrandchamps
- Service d'urologie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France.
| | - A Masson-Lecomte
- Service d'urologie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France.
| |
Collapse
|
8
|
Michel C, Masson-Lecomte A, Vordos D, Dumont C, Basset V, Meyer F, Gaudez F, Méria P, Cortesse A, Mongiat-Artus P, De la Taille A, Culine S, Desgrandchamps F. Impact de la chimiothérapie néoadjuvante sur la morbidité périopératoire de la cystectomie pour tumeur de vessie infiltrant le muscle. Prog Urol 2017. [DOI: 10.1016/j.purol.2017.07.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
9
|
Beurrier S, Vordos D, Allory Y, Chiarradia M, Yiou R, Hoznek A, De la Taille A, Salomon L, Masson-Lecomte A. Résultats oncologiques de la cystectomie totale pour tumeurs de vessie invasive chez les patients oligo-métastatiques ganglionnaires. Prog Urol 2016. [DOI: 10.1016/j.purol.2016.07.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Yiou R, De la taille A, Hoznek A, Salomon L, Vordos D. Pose de bandelette Virtue 4 bras pour incontinence urinaire masculine : bases anatomiques. Prog Urol 2016. [DOI: 10.1016/j.purol.2016.09.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
11
|
Amandine N, Masson-lecomte A, Mordoch J, Allory Y, Vordos D, Yiou R, Hoznek A, De la taille A, Salomon L. Le score de Gleason après prostatectomie totale de l’ISUP 2005 à l’ISUP 2014 : impact sur la survie sans récidive biologique : proposition d’un nouveau groupe pronostic. Prog Urol 2016. [DOI: 10.1016/j.purol.2016.07.210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
12
|
Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzeboc P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MAS, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BWG. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. Ann Oncol 2016; 27:1311-6. [PMID: 27091807 DOI: 10.1093/annonc/mdw170] [Citation(s) in RCA: 43] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2016] [Accepted: 04/06/2016] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Fibroblast growth factor receptor 3 (FGFR3) is an actionable target in bladder cancer. Preclinical studies show that anti-FGFR3 treatment slows down tumor growth, suggesting that this tyrosine kinase receptor is a candidate for personalized bladder cancer treatment, particularly in patients with mutated FGFR3. We addressed tumor heterogeneity in a large multicenter, multi-laboratory study, as this may have significant impact on therapeutic response. PATIENTS AND METHODS We evaluated possible FGFR3 heterogeneity by the PCR-SNaPshot method in the superficial and deep compartments of tumors obtained by transurethral resection (TUR, n = 61) and in radical cystectomy (RC, n = 614) specimens and corresponding cancer-positive lymph nodes (LN+, n = 201). RESULTS We found FGFR3 mutations in 13/34 (38%) T1 and 8/27 (30%) ≥T2-TUR samples, with 100% concordance between superficial and deeper parts in T1-TUR samples. Of eight FGFR3 mutant ≥T2-TUR samples, only 4 (50%) displayed the mutation in the deeper part. We found 67/614 (11%) FGFR3 mutations in RC specimens. FGFR3 mutation was associated with pN0 (P < 0.001) at RC. In 10/201 (5%) LN+, an FGFR3 mutation was found, all concordant with the corresponding RC specimen. In the remaining 191 cases, RC and LN+ were both wild type. CONCLUSIONS FGFR3 mutation status seems promising to guide decision-making on adjuvant anti-FGFR3 therapy as it appeared homogeneous in RC and LN+. Based on the results of TUR, the deep part of the tumor needs to be assessed if neoadjuvant anti-FGFR3 treatment is considered. We conclude that studies on the heterogeneity of actionable molecular targets should precede clinical trials with these drugs in the perioperative setting.
Collapse
Affiliation(s)
- D Pouessel
- Inserm U955, Hôpital Henri Mondor, APHP, Team 7 Translational Research of Genito-Urinary Oncogenesis, Créteil Department of Medical Oncology, Hôpital Saint-Louis, AP-HP, Paris, France
| | | | | | | | | | - J Sanders
- Pathology Molecular Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - D Peters
- Molecular Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | | | | | | | - P Soyeux
- Inserm U955, Hôpital Henri Mondor, APHP, Team 7 Translational Research of Genito-Urinary Oncogenesis, Créteil
| | | | - F Semprez
- Inserm U955, Hôpital Henri Mondor, APHP, Team 7 Translational Research of Genito-Urinary Oncogenesis, Créteil
| | - D Vordos
- Urology, Hôpital Henri Mondor, APHP, Créteil, France
| | - A de la Taille
- Inserm U955, Hôpital Henri Mondor, APHP, Team 7 Translational Research of Genito-Urinary Oncogenesis, Créteil Urology, Hôpital Henri Mondor, APHP, Créteil, France
| | - C D Hurst
- Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, UK
| | - D C Tomlinson
- Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, UK
| | - P Harnden
- Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, UK
| | - P J Bostrom
- Departments of Urology Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Centre, University of Toronto, Toronto
| | - T Mirtti
- Pathology, University of Turku, Turku, Finland
| | | | - Y Loriot
- Department of Cancer Medicine and INSERM U981, Gustave Roussy, Cancer Campus, Grand Paris, Villejuif
| | - N Houédé
- Department of Oncological Medicine, Institut Bergonié, Bordeaux
| | - C Chevreau
- Department of Oncological Medicine, Institut Claudius Régaud, Toulouse
| | - P Beuzeboc
- Department of Oncological Medicine, Institut Curie, Paris, France
| | - S F Shariat
- Departments of Urology Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria
| | | | - R Ashfaq
- Pathology, University of Texas, Southwestern Medical Center, Dallas, USA
| | - M Burger
- Department of Urology, Caritas St Josef Medical Centre, University of Regensburg, Regensburg, Germany
| | - M A S Jewett
- Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Centre, University of Toronto, Toronto
| | - A R Zlotta
- Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Centre, University of Toronto, Toronto Departments of Surgery (Urology)
| | - A Broeks
- Molecular Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - B Bapat
- Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto
| | - M A Knowles
- Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, UK
| | | | - T H van der Kwast
- Department of Pathology, University Health Network, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
| | - S Culine
- Department of Medical Oncology, Hôpital Saint-Louis, AP-HP, Paris, France Department of Medical Oncology, Paris 7 University, Paris
| | - Y Allory
- Inserm U955, Hôpital Henri Mondor, APHP, Team 7 Translational Research of Genito-Urinary Oncogenesis, Créteil Departments of Pathology Department of Pathology, Université Paris Est, UPEC, Créteil, France
| | - B W G van Rhijn
- Departments of Surgical Oncology (Urology) Department of Urology, Caritas St Josef Medical Centre, University of Regensburg, Regensburg, Germany Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Centre, University of Toronto, Toronto Departments of Surgery (Urology) Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto
| |
Collapse
|
13
|
Champy C, Salomon L, Cholley I, Hoznek A, Yiou R, Vordos D, Grimbert P, Lang P, De La Taille A. Prélèvement rénal de donneur vivant par laparoscopie robot-assistée avec extraction vaginale : mise à jour d’une série monocentrique. Prog Urol 2015; 25:723. [DOI: 10.1016/j.purol.2015.08.016] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
14
|
Champy C, Nicolaiew N, Cholley I, Vordos D, Hoznek A, Salomon L, De la taille A. Évolution du profil de 4501 patients candidats à une première série de biopsies prostatiques inclus sur 13ans dans un centre français. Prog Urol 2015; 25:828. [DOI: 10.1016/j.purol.2015.08.222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
15
|
Lioger B, Yahiaoui Y, Kahn JE, Fakhouri F, Belenfant X, Papo T, Magnant J, Maillot F, Vordos D, Godeau B, Michel M. [Retroperitoneal fibrosis in adults: Main characteristics and relevance of the diagnostic procedures based on a retrospective multicenter study on 77 cases]. Rev Med Interne 2015; 37:387-93. [PMID: 26415922 DOI: 10.1016/j.revmed.2015.08.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2015] [Revised: 06/21/2015] [Accepted: 08/20/2015] [Indexed: 12/31/2022]
Abstract
INTRODUCTION Retroperitoneal fibrosis (RPF) is a rare disorder characterized by the sheathing of retroperitoneal structures by fibro-inflammatory process. It can be either isolated or associated with an underlying disease or condition. In the absence of consistent and consensual approach, the objective of this study was to assess the relevance of diagnostic tests performed during the diagnostic work-up of RPF. METHODS Seventy-seven patients were included in this retrospective multicenter study. The diagnosis of RPF was defined by the presence of a thickened circumferential homogeneous tissue unsheathing the infrarenal aorta, excluding peri-aneurysmal fibrosis and a clear evidence of a cancer. RESULTS In 62 cases (80.5%), the RPF was considered as being primary or "idiopathic". Surgical (n=31) or CT-guided (n=9) biopsies of the RPF were performed in half of the patients showing some fibrotic or non-specific inflammatory lesions in 98% of cases. A bone marrow biopsy was performed in 23 patients leading to diagnosis of low grade B cell non-Hodgkin lymphoma in a single patient who also had a monoclonal gammopathy IgM. The systematic search for autoantibodies or serum tumor markers was of no diagnostic value. CONCLUSIONS Although the diagnostic procedure was heterogeneous, no cause or associated disease was found in the majority of cases of FRP in this series. In the absence of any clinical or paraclinical evidence suggesting an underlying disease or any atypical features at presentation, a number of non-invasive tests (autoantibodies, tumor markers, bone scintigraphy) and also more invasive diagnostic tests (bone marrow and RPF biopsies) seem of little relevance.
Collapse
Affiliation(s)
- B Lioger
- Service de médecine interne, université Francois-Rabelais, hôpital Bretonneau, CHU de Tours, 2, boulevard Tonnelé, 37044 Tours cedex 9, France.
| | - Y Yahiaoui
- Service de néphrologie, hôpital du Kremlin-Bicêtre, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, France
| | - J-E Kahn
- Service de médecine interne, hôpital Foch, 40, rue Worth, 92151 Suresnes cedex, France
| | - F Fakhouri
- Service de néphrologie et immunologie clinique, ITUN and Inserm UMR S-1064, CHU de Nantes, 44000 Nantes, France
| | - X Belenfant
- Service de néphrologie dialyse, hôpital André-Grégoire, 93100 Montreuil-sous-Bois, France
| | - T Papo
- Service de médecine interne, hôpital Bichat, 46, rue Henri-Huchard, 75018 Paris, France
| | - J Magnant
- Service de médecine interne, université Francois-Rabelais, hôpital Bretonneau, CHU de Tours, 2, boulevard Tonnelé, 37044 Tours cedex 9, France
| | - F Maillot
- Service de médecine interne, université Francois-Rabelais, hôpital Bretonneau, CHU de Tours, 2, boulevard Tonnelé, 37044 Tours cedex 9, France
| | - D Vordos
- Service d'urologie, hôpital Henri-Mondor, AP-HP, 94000 Créteil cedex, France
| | - B Godeau
- Service de médecine interne, centre de référence des cytopénies auto-immunes de l'adulte, université Paris-Est Créteil, hôpital Henri-Mondor, Assistance publique des Hôpitaux de Paris, 94000 Créteil, France
| | - M Michel
- Service de médecine interne, centre de référence des cytopénies auto-immunes de l'adulte, université Paris-Est Créteil, hôpital Henri-Mondor, Assistance publique des Hôpitaux de Paris, 94000 Créteil, France
| |
Collapse
|
16
|
Neuzillet Y, Rebouissou S, De Reynies A, Lepage M, Krucker C, Chapeaublanc E, Herault A, Kamoun A, Caillault A, Letouze E, Elarouci N, Decoux Y, Molinie V, Vordos D, Laplanche A, Maille P, Soyeux P, Ofualuka K, Reyal F, Biton A, Sibony M, Paoletti X, Southgate J, Benhamou S, Allory Y, Radvanyi F, Lebret T. L’Epidermal Growth Factor Receptor (EGFR) est une cible thérapeutique pour un sous-groupe de tumeurs de vessie agressives de phénotype de type basal. Prog Urol 2014; 24:806. [DOI: 10.1016/j.purol.2014.08.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
17
|
Saldana C, Chaubet-Houdu M, Joly C, Charbit D, Vordos D, Vacherot F, Salomon L, Tournigand C, De la Taille A. Cinétique du PSA comme facteur prédictif de réponse par acétate d’abiratérone chez les patients atteints d’un cancer de la prostate en phase de résistance à la castration. Prog Urol 2014; 24:818-9. [DOI: 10.1016/j.purol.2014.08.078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
18
|
Rebouissou S, Bernard-Pierrot I, de Reynies A, Lepage ML, Krucker C, Chapeaublanc E, Herault A, Kamoun A, Caillault A, Letouze E, Elarouci N, Neuzillet Y, Denoux Y, Molinie V, Vordos D, Laplanche A, Maille P, Soyeux P, Ofualuka K, Reyal F, Biton A, Sibony M, Paoletti X, Southgate J, Benhamou S, Lebret T, Allory Y, Radvanyi F. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med 2014; 6:244ra91. [DOI: 10.1126/scitranslmed.3008970] [Citation(s) in RCA: 237] [Impact Index Per Article: 23.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
19
|
Saldana C, Salomon L, Chaubet-Houdu M, Paule B, Tournigand C, Vordos D, Hoznek A, Abbou C, De La Taille A. Paclitaxel adjuvant en association avec une hormonothérapie versus une hormonothérapie seule chez les patients atteints d’un cancer de la prostate à haut risque de récidive après prostatectomie radicale. Prog Urol 2013. [DOI: 10.1016/j.purol.2013.08.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
20
|
Champy C, Salomon L, Campeggi A, De Fourmestraux A, Hoznek A, Yiou R, Vordos D, Grimbert P, Lang P, De La Taille A. Laparoscopie robot-assistée et néphrectomie chez le donneur vivant : une évolution naturelle de la technique de prélèvement. Prog Urol 2013. [DOI: 10.1016/j.purol.2013.08.228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
21
|
Rode J, Hoznek A, Campeggi A, De Fourmestraux A, Vordos D, taille ADL. Chirurgie percutanée miniaturisée en décubitus dorsal pour le traitement des calculs rénaux de 15mm et plus. Prog Urol 2013. [DOI: 10.1016/j.purol.2013.08.261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
22
|
Douard A, de la Taille A, Yiou R, Allory Y, Radulescu C, Vordos D, Hoznek A, Abbou CC, Salomon L. [Prognostic impact of tumors localized at the prostatic apex]. Prog Urol 2013; 23:405-9. [PMID: 23628099 DOI: 10.1016/j.purol.2013.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2012] [Revised: 01/31/2013] [Accepted: 02/07/2013] [Indexed: 11/19/2022]
Abstract
OBJECTIVE The apex is a particular region of the prostate in its surgical dissection and pathological analysis. We sought to evaluate the prognostic value of the apical localization of prostate tumors. METHOD From 1988 to 2010, data pre- (age, clinical stage, preoperative PSA, biopsy Gleason score) and postoperative (prostate weight, pathologic stage TNM 2010, Gleason score, margin status) of 2765 total prostatectomies were collected prospectively. These data were compared according to existence or absence of tumor at the apex. The prognostic impact of tumor at the apex on biochemical recurrence-free survival (PSA>0.2 ng/mL) has been studied in univariate and multivariate models. RESULTS One thousand eight hundred seventeen tumors had a location at the apex (65.7%). In univariate analysis, there was a significant difference in the clinical stage, the biopsy and pathological Gleason score, the result of curage, the pathological stage and the margin status between apical tumors and others. With a mean decline of 34.6 months, 502 patients had a biochemical recurrence (18.1%). Disease-free survival at 10 years was 60.7% for tumor at the apex versus 65.9% in other cases. The location at the apex was significantly associated with biochemical recurrence on univariate analysis (P=0.01). After adjustment for clinical and pathological stage, PSA level, Gleason score and surgical margins, the apex was not anymore a pejorative independent predictor (P=0.0087). CONCLUSION The existence of tumor in the prostatic apex was associated with more aggressive tumoral criteria and was an independent and pejorative predictor of biochemical recurrence-free survival at 10 years in univariate analysis. The apical localization could be an additional argument in the decision of adjuvant therapy after prostatectomy.
Collapse
Affiliation(s)
- A Douard
- Service d'urologie, centre hospitalier de la Côte Basque, 64100 Bayonne, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Masson-Lecomte A, Vordos D, de la Taille A, Neuzillet Y, Radvanyi F, Allory Y. [Update on FGFR3 mutation and multiple regional epigenetic silencing (MRES) phenotype in urothelial carcinogenesis]. Prog Urol 2013; 23:96-8. [PMID: 23352301 DOI: 10.1016/j.purol.2012.12.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2012] [Revised: 10/15/2012] [Accepted: 12/02/2012] [Indexed: 10/27/2022]
Abstract
FGFR3 mutation leads to a constitutive activation of the receptor 3 to Fibroblast Growth Factor. This mutation is early in urothelial carcinogenesis and is strongly associated to low grade papillary tumors. Multiple regional epigenetic silencing (MRES) phenotype corresponds to the transcriptional inactivation of chromosomal regions in muscle invasive bladder cancer, and is strongly associated to the molecular signature of carcinoma in situ. These alterations could be targeted by new specific therapies.
Collapse
Affiliation(s)
- A Masson-Lecomte
- Inserm U955 équipe 7, service d'urologie, université Paris-Est Créteil, CHU Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France.
| | | | | | | | | | | |
Collapse
|
24
|
Basset V, Nicolaiew N, Ruffion A, Villers A, Houlgatte A, Allory Y, Salomon L, Vordos D, Abbou CC, De La Taille A. Analyse du profil de 10654 patients candidats à une première série de biopsies prostatiques inclus sur dix ans dans quatre centres français. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
25
|
El Hajj A, Defourmestraux A, Yiou R, Vordos D, Hoznek A, Salomon L, Abbou C, De La Taille A. Prostatectomie radicale robotique de rattrapage après radiothérapie. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
26
|
Masson-Lecomte A, Vordos D, Hoznek A, Yiou R, Abbou C, De La Taille A, Salomon L. Impact de l’invasion musculaire sur les résultats oncologiques de la cystectomie pour tumeur résistante au BCG. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
27
|
Masson-Lecomte A, Vordos D, Gillion N, Hoznek A, Yiou R, Allory Y, Abbou C, De La Taille A, Salomon L. Résultats oncologiques à long terme de la pelvectomie antérieure versus cystectomie seule pour carcinome urothélial chez la femme. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
28
|
Basset V, De Fourmestraux A, Campeggi A, Allory Y, Vordos D, Yiou R, Hoznec A, Abbou C, De La Taille A, Salomon L. Rôle de la longueur totale d’effraction capsulaire sur la survie sans récidive biologique en cas tumeur de stade pt3a n0 après prostatectomie totale. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
29
|
Ouzaid I, Xylinas E, Allory Y, Vordos D, Abbou C, Salomon L, De La Taille A, Ploussard G. Indice de masse corporelle et cancer de la prostate : éléments histo-pronostiques sur les biopsies et les pièces de prostatectomies totales. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
30
|
Yiou R, Ebrahimina V, Bedretdinova D, Mouracade P, Taille ADL, Salomon L, Vordos D, Hoznek A, Abbou C. Déterminants de la vie sexuelle des partenaires des patients prostatectomisés utilisant des injections intracaverneuses de prostaglandine. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
31
|
Richard R, Bouanane M, Salomon L, Vordos D, Pigneur F, Werbrouck A, Rahmouni A, Luciani A. [Urachus pathology: infected urachal cyst]. ACTA ACUST UNITED AC 2011; 92:250-3. [PMID: 21501765 DOI: 10.1016/j.jradio.2011.02.009] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2010] [Revised: 02/14/2011] [Accepted: 02/15/2011] [Indexed: 11/16/2022]
|
32
|
Xylinas E, Durand X, Campeggi A, Ploussard G, Allory Y, Vordos D, Hoznek A, De La Taille A, Abbou CC, Salomon L. Surveillance active du cancer de prostate ayant des critères de latence : les critères SURACAP sont-ils suffisants ? Prog Urol 2011; 21:264-9. [DOI: 10.1016/j.purol.2010.09.021] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2010] [Revised: 07/28/2010] [Accepted: 09/29/2010] [Indexed: 10/18/2022]
|
33
|
Xylinas E, Ploussard G, Paul A, Gillion N, Vordos D, Hoznek A, De La Taille A, Abbou CC, Salomon L. Prostatectomie radicale laparoscopique chez la personne âgée (>75ans) : résultats carcinologiques et fonctionnels. Prog Urol 2010; 20:116-20. [DOI: 10.1016/j.purol.2009.08.037] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2009] [Revised: 08/17/2009] [Accepted: 08/20/2009] [Indexed: 10/20/2022]
|
34
|
Bakkar AA, Allory Y, Iwatsubo Y, de Medina SGD, Maille P, Khreich N, Riou A, Leroy K, Vordos D, Abbou CC, Andujar P, Billebaud T, Chammings S, Conso F, De La Taille A, Fontaine E, Gattegno B, Ravery V, Sibony M, Radvanyi F, Chopin DK, Pairon JC. Occupational exposure to polycyclic aromatic hydrocarbons influenced neither the frequency nor the spectrum of FGFR3 mutations in bladder urothelial carcinoma. Mol Carcinog 2010; 49:25-31. [PMID: 19722178 DOI: 10.1002/mc.20573] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Occupational exposure to polycyclic aromatic hydrocarbons (PAH) is associated with an increased risk of urothelial carcinoma (UC). FGFR3 is found mutated in about 70% of Ta tumors, which represent the major group at diagnosis. The influence of PAH on FGFR3 mutations and whether it is related to the emergence or shaping of these mutations is not yet known. We investigated the influence of occupational PAH on the frequency and spectrum of FGFR3 mutations. We included on 170 primary urothelial tumors from five hospitals from France. Patients (median age, 64 yr) were interviewed to gather data on occupational exposure to PAH, revealing 104 non- and possibly PAH exposed patients, 66 probably and definitely exposed patients. Tumors were classified as follows: 75 pTa, 52 pT1, and 43 > or =pT2. Tumor grades were as follows: 6 low malignant potential neoplasms (LMPN) and 41 low-grade and 123 high-grade carcinomas. The SnaPshot method was used to screen for the following FGFR3 mutations: R248C, S249C, G372C, Y375C, A393E, K652E, K652Q, K652M, and K652T. Occupational PAH exposure was not associated with a particular stage or grade of tumors. Thirty-nine percent of the tumors harbored FGFR3 mutations. After adjustment for smoking, occupational exposure to PAH did not influence the frequency [OR, 1.10; 95% CI, 0.78-1.52], or spectrum of FGFR3 mutations. Occupational exposure to PAH influenced neither the frequency nor the spectrum of FGFR3 mutations and there was no direct relationship between these mutations and this occupational hazard.
Collapse
|
35
|
Ploussard G, Paule B, Salomon L, Allory Y, Terry S, Vordos D, Hoznek A, Vacherot F, Abbou CC, Culine S, de la Taille A. Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life. Prostate Cancer Prostatic Dis 2009; 13:97-101. [PMID: 19935771 DOI: 10.1038/pcan.2009.51] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Therapeutic strategy remains unclear with no clear consensus for men with high-risk prostate cancer (PCa) after radical prostatectomy. We aimed to evaluate into a prospective randomized trial the effectiveness and feasibility of adjuvant weekly paclitaxel combined with androgen deprivation therapy (ADT) in these patients. A total of 47 patients with high-risk PCa were randomized 6 weeks after radical prostatectomy: ADT alone versus combination of ADT and weekly paclitaxel. Toxicity, quality-of-life and functional results were compared between the two arms. All 23 patients completed eight cycles of paclitaxel. Toxicity was predominantly of grade 1-2 severity. There were no differences in EORTC QLQ-C30 scores between the two groups and between baseline and last assessment at 24 months after surgery. Urinary continence was complete at 1 year after surgery for all patients and no significant differences were noted at each assessment between the two groups. The interim analysis of this trial confirms the feasibility of weekly paclitaxel in combination with ADT in men at high-risk PCa with curative intent. This adjuvant combined therapy does not alter quality-of-life and continence recovery after surgery plus ADT. A larger cohort is awaited to determine the oncological outcomes of this strategy.
Collapse
Affiliation(s)
- G Ploussard
- INSERM U955 Eq07 Department of Urology, APHP, CHU Henri Mondor, Créteil, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
De Laet K, de la Taille A, Ploussard G, Hoznek A, Vordos D, Yiou R, Allory Y, Azoulay S, Abbou C, Salomon L. Predicting tumour location in radical prostatectomy specimens: same-patient comparisons of 21-sample versus sextant biopsy. BJU Int 2009; 104:616-20. [DOI: 10.1111/j.1464-410x.2009.08468.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
37
|
Diao B, Allory Y, Vordos D, De La Taille A, Abbou CC, Salomon L. [Lymphoepithelioma-like carcinoma of the bladder: a new case report and literature review]. Prog Urol 2009; 19:576-8. [PMID: 19699457 DOI: 10.1016/j.purol.2009.03.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2009] [Revised: 03/24/2009] [Accepted: 03/31/2009] [Indexed: 11/19/2022]
Abstract
Lymphoepithelioma-like carcinoma of the bladder is rare tumour which is called so because of the histological similitude with lymphoepithelioma carcinoma of nasopharynx. Its pathogenic aspects have been unknown and conservative treatment has taken a main place in the management of pure cases. The authors report a new case and discuss pathogenic aspects, prognosis factors and therapeutic aspects.
Collapse
Affiliation(s)
- B Diao
- Service d'urologie, hôpital Henri-Mondor, 51, avenue Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France.
| | | | | | | | | | | |
Collapse
|
38
|
Larré S, Kanso C, De La Taille A, Hoznek A, Vordos D, Yiou R, Abbou CC, Salomon L. Retroperitoneal laparoscopic radical nephrectomy: Intermediate oncological results. World J Urol 2008; 26:611-5. [DOI: 10.1007/s00345-008-0306-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2008] [Accepted: 06/23/2008] [Indexed: 11/24/2022] Open
|
39
|
Rodriguez-Covarrubias F, Larré S, Dahan M, De La Taille A, Allory Y, Yiou R, Vordos D, Hoznek A, Abbou CC, Salomon L. Invasion of bladder neck after radical prostatectomy: one definition for different outcomes. Prostate Cancer Prostatic Dis 2007; 11:294-7. [PMID: 17876340 DOI: 10.1038/sj.pcan.4501009] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The aim of the study was to evaluate factors of progression after radical prostatectomy in patients with bladder neck invasion (BNI). From 1988 to 2006, 1395 patients underwent radical prostatectomy, 120 (8.6%) had microscopic BNI (pT4 N0, TNM 2002). Group 1 was defined as BNI alone, group 2 as BNI plus extracapsular extension and group 3 as BNI plus seminal vesicle invasion (SVI). Postoperative follow-up data were obtained through routine serum prostate-specific antigen (PSA) and digital rectal examination. Biochemical progression was defined as a single detectable PSA level postoperatively (>0.2 ng ml(-1)). Groups 1, 2 and 3 included 38 (31%), 35 (30%) and 47 (39%) patients, respectively. Preoperative PSA (11.1 vs 24.7 and 23.3 ng ml(-1), P=0.01), biopsy Gleason score (5 vs 6 and 6, P=0.003) and specimen Gleason score (6 vs 7 and 7, P=0.02) were statistically different between three groups. None of the patients had a specimen Gleason score >or=8 in group 1. After a mean follow-up of 27 months, 51 (42.5%) patients had biochemical progression. The 5-year progression-free survival was 87, 53 and 17% for groups 1, 2 and 3, respectively (P<0.001). Within pT4 prostate cancer, those tumors with isolated microscopic BNI appear to have better prognosis than those with associated extracapsular extension and/or seminal vesicle invasion, and should be distinguished in TNM classification.
Collapse
|
40
|
Andujar P, Vordos D, Conso F, Gattegno B, Ravery V, Fontaine E, Billebaud T, Chamming's S, Berthaut C, Iwatsubo Y, Chopin D, Abbou C, Pairon J. Société française de médecinedu travail Séance du 15 octobre 2005, Paris. ARCH MAL PROF ENVIRO 2006. [DOI: 10.1016/s1775-8785(06)70475-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
41
|
Goeman L, Salomon L, Hoznek A, De La Taille A, Vordos D, Yiou R, Abbou CC. Radical laparoscopic prostatectomy: should we do bladder neck preservation or a reconstruction? Curr Urol Rep 2006; 7:93-5. [PMID: 16526991 DOI: 10.1007/s11934-006-0065-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
42
|
Nicolle G, Daher A, Maillé P, Vermey M, Loric S, Bakkar A, Wallerand H, Vordos D, Vacherot F, de Medina SGD, Abbou CC, Van der Kwast T, Thiery JP, Radvanyi F, Chopin DK. Gefitinib Inhibits the Growth and Invasion of Urothelial Carcinoma Cell Lines in which Akt and MAPK Activation Is Dependent on Constitutive Epidermal Growth Factor Receptor Activation. Clin Cancer Res 2006; 12:2937-43. [PMID: 16675591 DOI: 10.1158/1078-0432.ccr-05-2148] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Abnormally high levels of epidermal growth factor receptor (EGFR) protein are associated with advanced tumor stage/grade. The objective of this study was to evaluate the effects of the specific EGFR tyrosine kinase inhibitor gefitinib on activation of the Akt and mitogen-activated protein kinase (MAPK) pathways in human urothelial cell carcinoma (UCC) cell lines and to identify potential markers of gefitinib responsiveness in biopsy samples of UCC. EXPERIMENTAL DESIGN Changes in markers of UCC growth and invasion after exposure to gefitinib were studied in six human UCC cell lines expressing various levels of EGFR. The findings were related to activation of Akt and MAPK. We studied the influence of gefitinib on intraepithelial expansion of the responsive 1207 cell line. EGFR, Akt, and MAPK activation was studied by Western blot analysis of a panel of 57 human UCC. RESULTS Gefitinib had a growth-inhibitory and anti-invasive effect in two of six UCC cell lines (i.e., 647V and 1207). Gefitinib was also able to block the expansion of 1207 at the expense of normal urothelial cells. These effects did not depend on the level of expression of EGFR but they were associated with the down-regulation of MAPK and Akt activity; in 1207 cells, gefitinib activity was associated with p27 up-regulation and p21 and matrix metalloproteinase-9 down-regulation. Similarly, the Akt and MAPK pathways were found to be strongly phosphorylated in association with EGFR activation in a subset of human UCC specimens. CONCLUSIONS Activation of EGFR, Akt, and MAPK defines a subset of UCC which might provide information for the identification of gefitinib responders.
Collapse
Affiliation(s)
- Gaëlle Nicolle
- Institut National de la Sante et de la Recherche Medicale, EMI 03-37, Faculté de Médecine, Université Paris XII, Créteil, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Ménard Y, Guichard G, Hoznek A, De La Taille A, Yiou R, Vordos D, Allory Y, Abbou CC, Salomon L. 1145: Comparison of Laparoscopic Radical Prostatectomy with and without Previous Trans Urethral Prostate Resection. J Urol 2006. [DOI: 10.1016/s0022-5347(18)33370-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
44
|
Abstract
The current system of surgical education is facing many challenges in terms of time efficiency, costs, and patient safety. Training using simulation is an emerging area, mostly based on the experience of other high-risk professions like aviation. The goal of simulation-based training in surgery is to develop not only technical but team skills. This learning environment is stress-free and safe, allows standardization and tailoring of training, and also objectively evaluate performances. The development of simulation training is straightforward in endourology, since these procedures are video-assisted and the low degree of freedom of the instruments is easily replicated. On the other hand, these interventions necessitate a long learning curve, training in the operative room is especially costly and risky. Many models are already in use or under development in all fields of video-assisted urologic surgery: ureteroscopy, percutaneous surgery, transurethral resection of the prostate, and laparoscopy. Although bench models are essential, simulation increasingly benefits from the achievements and development of computer technology. Still in its infancy, virtual reality simulation will certainly belong to tomorrow's teaching tools.
Collapse
Affiliation(s)
- András Hoznek
- Service d'Urologie, Centre Hospitalier Universitaire Henri Mondor, Université Paris XII, 51. Av;du Ml. De Lattre de Tassigny, 94010 Créteil-cedex, France.
| | | | | | | | | | | | | |
Collapse
|
45
|
Haber GP, Gill IS, Rozet F, Cathelineau X, Barret E, Vallancien G, Sterrett S, Balaji KC, Van Velthoven R, Game X, Rischmann P, Abdel-Hakim AM, Vordos D, Abbou CC, Castillo OA, Simonato A, Borin JF, Ornstein DK, Shanberg AM. 1224: International Registry of Laparoscopic Radical Cystectomy: First Report on 308 Patients. J Urol 2006. [DOI: 10.1016/s0022-5347(18)33437-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
46
|
Goeman L, Salomon L, La De Taille A, Vordos D, Hoznek A, Yiou R, Abbou CC. Long-term functional and oncological results after retroperitoneal laparoscopic prostatectomy according to a prospective evaluation of 550 patients. World J Urol 2006; 24:281-8. [PMID: 16508788 DOI: 10.1007/s00345-006-0054-6] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2006] [Accepted: 01/26/2006] [Indexed: 11/26/2022] Open
Abstract
The objective of the study was to evaluate the long-term results of retroperitoneal laparoscopic radical prostatectomy (LRP). From 2001 to 2005, 550 consecutive patients underwent a laparoscopic extraperitoneal prostatectomy in our department. Continence and erectile function were analysed prospectively by a self-administrated questionnaire. Mean operating time was 188 min, mean bladder catheterisation time 5.9 days, mean hospital stay 4.6 days Pathological stage was pT2 in 55.8%, pT3a in 29.6%, pT3b in 9.1% and pT4a in 5.4% tumours. Positive surgical margins were 17.9% for pT2, 44.8% for pT3 tumours and 71.4% for pT4a tumours. Five years survival without biochemical progression was 78.8%. After 24 months of follow-up, diurnal continence rate was 91%, and potency rate was 64% when both neurovascular bundles were preserved, 78.6% when the patients were younger than 60 years. LRP is now a standardised procedure. An extraperitoneal approach combines the advantages of a laparoscopic procedure with those of an extraperitoneal approach.
Collapse
Affiliation(s)
- L Goeman
- Department of Urology, Henri Mondor Hospital, 51 Avenue du Ml. De Lattre de Tassigny, 94010, Créteil, France
| | | | | | | | | | | | | |
Collapse
|
47
|
Nicole G, Vordos D, Daher A, Maillé P, Bakkar A, Pages C, Jouault H, Abbou CC, Gil Diez de Medina S, Chopin DK. 578: Gefitinib, A Pharmacological Inhibitor of EGFR Inhibits Growth and Invasion of Urothelial Cell Lines in Which ERBB1 is Constitutively Activated. J Urol 2005. [DOI: 10.1016/s0022-5347(18)34818-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
48
|
Hoznek A, Vordos D, Gettman MT, Salomon L, De La Taille A, Yiou R, Abbou CC. V1348: Laparoscopic Radical Cystectomy with Orthotopic Ileal Neobladder. J Urol 2005. [DOI: 10.1016/s0022-5347(18)35899-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
49
|
Antiphon P, Elard S, Benyoussef A, Fofana M, Yiou R, Gettman M, Hoznek A, Vordos D, Chopin DK, Abbou CC. Laparoscopic promontory sacral colpopexy: is the posterior, recto-vaginal, mesh mandatory? Eur Urol 2004; 45:655-61. [PMID: 15082210 DOI: 10.1016/j.eururo.2004.01.004] [Citation(s) in RCA: 84] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/06/2004] [Indexed: 01/03/2023]
Abstract
OBJECTIVE(S) The aim of our retrospective study was to determine if systematic placement of a posterior mesh, in addition to an anterior vesico-vaginal mesh, is necessary for laparoscopic treatment of pelvic organ prolapse. METHODS A laparoscopic promontory sacral colpopexy was performed in 108 patients, including 55 patients with a concurrent laparoscopic Burch procedure (50.9%). We compared 33 patients treated with a single anterior mesh (SAM) and 71 treated with a double, anterior and posterior, mesh (DM). RESULTS The difference between the SAM and DM groups was statistically significant in terms of posterior compartment failure (rectocele and/or enterocele): 31.3% and 5.9%, respectively (p=0.0006). This significant difference persisted in the Burch (B) group (p=0.001), but not in the non-Burch (NB) group (p=0.98). Among the SAM group, this difference between the B and NB groups, was significant (57.1% versus 0%; p=0.0015) and above all not a single posterior failure was observed in the NB group. CONCLUSION(S) The placement of a posterior mesh, if highly effective, appeared unnecessary in the absence of an associated Burch procedure or a patent posterior prolapse. The posterior mesh also increased risk of postoperative complications and side effects.
Collapse
Affiliation(s)
- P Antiphon
- Service d'Urologie, Hôpital Henri Mondor, Créteil, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Ruiz L, Salomon L, Hoznek A, Vordos D, Yiou R, de la Taille A, Abbou CC. Comparison of Early Oncologic Results of Laparoscopic Radical Prostatectomy by Extraperitoneal versus Transperitoneal Approach. Eur Urol 2004; 46:50-4; discussion 54-6. [PMID: 15183547 DOI: 10.1016/j.eururo.2004.04.013] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/19/2004] [Indexed: 10/26/2022]
Abstract
PURPOSE Compare the early oncological results of laparoscopic radical prostatectomy performed by either an extraperitoneal or a transperitoneal approach. METHODS 330 consecutive men underwent laparoscopic radical prostatectomy for localized prostate cancer, the first 165 by transperitoneal approach, and the last 165 by extraperitoneal approach. Clinical stage, serum PSA, Gleason score of biopsy were recorded, as well as operating time, surgical and medical complications, blood loss, length of hospital stay and catheterization time. The weight of the specimen, pathological stage (1997 TNM classification) and status of the surgical margins were noted. The Fisher test as well as the chi2-test were used for statistical analysis. Differences were considered significant when p < 0.05. RESULTS There were no significant differences between the two groups in terms of preoperative characteristics except for Gleason score of the biopsies which was higher in the extraperitoneal group (p < 0.0001). The operating time was longer with the transperitoneal approach (248.5 min vs. 220.0 min, p < 0.0001). There was no difference in transfusion rate (1.2% vs. 5.4%, transperitoneal vs. extraperitoneal, respectively, p = 0.6). There was no difference in hospital stay, medical and surgical complications. Respectively, in the transperitoneal and extraperitoneal groups, there were 108 and 88 pT2 tumors. There were no differences in terms of positive surgical margins between the two groups, 23% and 29.7% (p = 0.21) overall, 13.0% and 17.0% (p = 0.42) in pT2 tumors and 43.6% and 44.7% (p = 0.99) in pT3 tumors. CONCLUSIONS Extraperitoneal approach offers the same early oncological results as transperitoneal approach with a shorter operative time.
Collapse
Affiliation(s)
- Leticia Ruiz
- Service d'Urologie CHU Henri Mondor, 51. Av. Du Ml. de Lattre de Tassigny, 94010 Créteil cedex, France
| | | | | | | | | | | | | |
Collapse
|